These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 29025909)

  • 41. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].
    Ishii T
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):167-71. PubMed ID: 24107520
    [No Abstract]   [Full Text] [Related]  

  • 42. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
    Piekarz RL; Robey RW; Zhan Z; Kayastha G; Sayah A; Abdeldaim AH; Torrico S; Bates SE
    Blood; 2004 Jun; 103(12):4636-43. PubMed ID: 14996704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
    Ishii Y; Itabashi M; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
    Intern Med; 2016; 55(6):673-5. PubMed ID: 26984089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
    Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
    Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
    [No Abstract]   [Full Text] [Related]  

  • 45. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
    Kanno K; Honma M; Ishida-Yamamoto A
    J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
    [No Abstract]   [Full Text] [Related]  

  • 46. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Yonekura K; Tashiro Y; Tokunaga M; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Inagaki H
    Blood; 2018 Aug; 132(7):758-761. PubMed ID: 29930010
    [No Abstract]   [Full Text] [Related]  

  • 48. CCR4 and its ligands: from bench to bedside.
    Yoshie O; Matsushima K
    Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
    Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody.
    Sugata K; Yasunaga J; Miura M; Akari H; Utsunomiya A; Nosaka K; Watanabe Y; Suzushima H; Koh KR; Nakagawa M; Kohara M; Matsuoka M
    Sci Rep; 2016 Jun; 6():27150. PubMed ID: 27250643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
    Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
    Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
    Ishitsuka K; Murahashi M; Katsuya H; Mogi A; Masaki M; Kawai C; Goto T; Ishizu M; Ikari Y; Takamatsu Y; Ishibashi H; Nimura S; Takeshita M; Tamura K
    Int J Hematol; 2015 Oct; 102(4):493-7. PubMed ID: 25995001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.
    Ishida T; Inagaki H; Utsunomiya A; Takatsuka Y; Komatsu H; Iida S; Takeuchi G; Eimoto T; Nakamura S; Ueda R
    Clin Cancer Res; 2004 Aug; 10(16):5494-500. PubMed ID: 15328188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mogamulizumab: first global approval.
    Subramaniam JM; Whiteside G; McKeage K; Croxtall JC
    Drugs; 2012 Jun; 72(9):1293-8. PubMed ID: 22686619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
    Watanabe K; Gomez AM; Kuramitsu S; Siurala M; Da T; Agarwal S; Song D; Scholler J; Rotolo A; Posey AD; Rook AH; Haun PL; Ruella M; Young RM; June CH
    Blood Adv; 2023 Jul; 7(14):3416-3430. PubMed ID: 37058474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
    Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.